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Introduction. Patient waiting time for specialist consultations in oncology had ranged from a few to several weeks 
in 2013. This was due to there being insufficient physicians in oncology, an uneven distribution of cancer centres and 
that referrals were not necessarily required for attending cancer out-patient clinics. After introducing the ‘Diagnosis 
and Treatment of Cancer’ (DILO) card, reduced waiting times were intended. 
Materials and methods. A retrospective study was undertaken at the hospital workplace to analyse reasons for 
referral in 1124 patients registering for the first time at the Cancer Clinic in Wejherowo in 2015, where those with or 
without DILO cards were compared. In cases of referrals for which cancer was suspected, clinical and histopathological 
or cytological investigations were performed. Those qualifying for radical oncological treatment were also counted in.
Results. For most cases the reasons for oncological referral using DILO cards were found to be pathologies detected 
by imaging tests, whereas few diagnoses were made that were based on either cytological or histopathological test-
ing, or indeed by any abnormalities observed from physical examination.
Conclusions. Based on the outcomes and experience of the authors, a practical set of guidelines has been proposed 
when making patient referrals to cancer out-patient clinics for consultation. Coupled with this, GPs’ increased knowl-
edge on cancer may serve to lessen the number of referrals to cancer out-patient clinics. Thus, access to oncological 
consultations would become facilitated. 
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Introduction
In Poland, General Practioner (GP) referrals are for the 
most part required for obtaining specialist appointments 
where the waiting time to the first visit varies between 
a few to several weeks. These times also apply when seeing 
oncologists, despite referrals not being needed. One of the 
reasons why the DILO card based system was set up was to 
shorten waiting times between when cancer is diagnosed 
to when it is treated. According to the Central Registry of 
Doctors, as managed by the Polish Chamber of Physicians, 
the numbers of doctors/medical practitioners specialising 
in oncology in Poland are 818 which includes 806 that are 
actively practicing [1]. Bearing in mind the population of 
Poland, of over 38.45 million, then there are 2.1 oncologists 
per 100,000 (i.e. 1 oncologist per 55,000). In 2013, these 
respectively amounted to 1.9 oncologists per 100,000 and 
1 per 55,000 [2, 3]. 
Compared to 2013, (when our first reports were pub-
lished), there are still 3 oncological centres/departments in 
the Pomeranian region (voivodeship) where there is a great 
onus placed on out-patient treatment [3]. During this time, 
the Department of Outpatient Chemotherapy at the Medical 
University of Gdansk was created and the Regional (Voivode-
ship) Oncology Centre became joined to the ‘Copernicus 
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Medical Centre’. Smaller centres have likewise extended their 
range of services for cancer patients. So far, our previous 
2013 study, the number of patients receiving chemotherapy 
has doubled at our Specialist Hospital in Wejherowo and 
the Department of General Surgery has been transformed 
into the Department of General and Oncological Surgery. 
All these changes are aimed to improve the availability of 
multi-disciplinary healthcare, that includes oncology. 
At present, there are 42 oncologists in the Pomeranian 
region, including 36 that are in active practice [1]; in 2013, 
these were correspondingly 40 and 34 [3]. The European Un-
ion (EU) standard is 1 oncologist per 60,000. The Pomeranian 
region boasts 1 oncologist per 55,500, nevertheless access to 
this specialisation still appears inadequate, where possible 
reasons could be a lack of set guidelines for the GP in refer-
ring patients to oncologists as well as the right of patients 
in seeking such consultations without their GP’s referral; this 
being pointed out in our previous publication. One of the 
postulates/premises of the DILO system was to deal with this 
problem. On the official website www.pakietonkologiczny.
gov.pl one can read that patients first need to see their GP 
who should conduct an interview for assessing the patient’s 
ailment(s) and, if so required, issue a referral for tests vital for 
diagnosing cancer; if proved to be the case, then the patient 
is then referred to a specialist or oncologist. 
In our subjective opinion, it is exactly these types of 
provisions that are likely to lead to an excess of referrals to 
oncologists being issued without prior histopathology or 
cytology testing nor any additional tests being performed, 
thereby putting increasing burdens on the oncologist. This 
has become the reason we have decided to re-analyse pa-
tient referrals made to the Cancer Clinic in Wejherowo, es-
pecially taking into consideration referrals made according 
to the DILO scheme. Introducing the ‘Oncological Package’ 
has caused several changes, both in legal terms as well as 
in the competencies of GPs and outpatient care specialists 
(AOS) along with changing several previously obligatory 
practices in how patients suspected of cancer are diagnosed 
and treated. However, this is clearly not comparable to the 
situation in 2013. The Cancer Clinic in Wejherowo provides 
services both under the DILO card scheme as well as under 
the so-called ‘Old System’ of out-patient care. According 
to the DILO system, our clinic performs both initial and 
detailed diagnoses where furthermore, our doctors take 
part in multi-disciplinary consultative meetings with other 
departments of our hospital. 
Materials and methods
The Cancer Clinic in Wejherowo operates within the 
F. Ceynowa Memorial Regional Hospital and is contracted by 
the National Health Insurance scheme to deliver oncologi-
cal services/consultation and out-patient chemotherapy. 
It is open 5 days a week, where 3 experienced clinical on-
cologists receive patients from the Pomeranian Region, 
together with 2 radiotherapists, 3 surgical oncologists, 
one pulmonary specialist and one urologist; this being 3 
more doctors than in 2013. Our clinical oncologists deliver 
healthcare services in chemotherapy and both initial and 
detailed diagnoses under the DILO scheme, where they 
provide specialist consultation in oncology and participate 
in multi-disciplinary consultative meetings as well as being 
consultants for patients at other hospital departments. The 
hospital covers the town of Wejherowo and its local district 
as well as surrounding districts from the Pomeranian Region 
along with the city of Gdynia to the east of Wejherowo; in the 
latter case, most patients are sent to the Gdansk Oncology 
Centre for their treatment. In total, these regions constitute 
approximately 550,000 inhabitants [2].
Our study was based on the retrospective analyses 
of patient records such as: referrals sent by GPs and doc-
tors of other specialisations as well as filled in DILO cards 
and documented records of the patient’s observations 
and treatment course at the Specialist Hospital in Wej-
herowo along with those referrals resulting from consul-
tative meetings from other centres possessing greater 
referentialities. The study was performed in 2016. Medical 
documentation from 1124 patients were analysed who had 
attended our Cancer Clinic from 1st January 2015 till 31st 
December 2015. Those suffering diseases were qualified 
for further analyses. 
For the purposes of discussion, patients were divided 
into 2 groups. The first were those who came to our clinic 
without DILO cards, whilst the second were those with such 
cards obtained from their GPs or doctors with other speciali-
sations; this also included patients who were issued DILO 
cards by our clinic. Patient characteristics of both these 
groups are presented in Table I and respectively constituted 
54.4% and 45.6% of the total. The reasons behind the refer-
rals made to our Cancer Clinic that were issued by GPs or 
specialist doctors under DILO scheme were divided into 
4 groupings: 
 — Referral for diagnostics based on patient interview and/ 
/or abnormalities upon physical examination;
 — Abnormalities from additional testing (including imag-
ing, such as rounded shadows upon chest X-ray, tumours 
detected by ultrasonography of the abdomen, pelvis, 
breast, or thyroid and abnormal laboratory test results);
 — Diagnosis of cancer through histopathology or cytology;
 — Those patients not classified in the above groupings 
were qualified into a fourth group under ‘others’.
The study was authorised by our hospital Director. 
A condition however being that complete anonymity is 
maintained throughout for the patient subjects when pre-
paring databases. Statistics was performed using Microsoft 
Office Excel 2003 and the PQSTAT 1.4 programme. The Fisher 
Exact Test and Mann Whitney Test were used respectively 
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on categorical and continuous variables, taking significance 
as being p ≤ 0.05.
Results
Patient demographics
Women subjects constituted a majority in the study 
group of 1124 patients at n = 745 (i.e. 66.3%), with their 
mean age in the DILO card scheme being significantly higher 
than non-DILO card women; respectively 62 and 52 years 
(p < 0.01). No such differences were observed for men. 
Women were more prevalent at younger ages. There were 
significantly more women and men aged 18–39 years than 
those aged above 60 years (p < 0.01) and significantly more 
men and women aged 40–59 years than those aged above 
60 years (p < 0.05). A decided majority of subjects (57.3%) 
lived in towns (urban dwellers); 35.6% in Wejherowo itself 
and other towns in the vicinity at 21.7%. There were 42.7% 
patients living in the countryside (rural areas). Most subjects 
attending from towns (towns and villages) lived within 
a radius of 50 km of the Wejherowo Cancer Clinic. Most study 
patients (54%) were referred either from Wejherowo or its 
local district. Others (27%) lived in the Puck district and 10% 
in the Lebork district.
GP referral data to the Clinic
Table II details the patient referral data (from GPs or other 
doctors) according to the four groupings, considering DILO 
and non-DILO card referral status. The largest grouping was 
those where cancer was diagnosed by cytology or histopa-
thology (38.8%) where the most common cancers found 
were: the lung (36%), breast (18%), colon (15%), prostate 
(5%) and bladder (4%). Other cancers did not exceed 3%. 
GP referral data to the Clinic for  
non-DILO card-bearing patients
Because patients coming to the Cancer Clinic do not 
formally require referrals, most of them declare that they 
were recommended to come by their doctors. It was found 
that 11% of those with formal referrals had a cancer history. 
In the entire group, prophylactic referrals for breast cancer 
predominated. In the 286 women referred to the Cancer 
Clinic, most were aged either 40–49 years or over 60 years 
and who had undergone breast cancer prevention testing 
compared to those aged 50–69 years (p < 0.05). The reasons 
for referring women of those ages embraced by the breast 
prevention programme were most frequently concerns 
about having cancer and being a burden to their families. 
From the 286 women, cancer was found in only one, how-
ever breast changes requiring treatment were found in two. 
In addition, abnormalities in breast imaging were detected 
in 6% in this women’s group requiring supplementary di-
agnostics by means of a fine needle aspiration biopsy. The 
second most commonly referred group to the Cancer Clinic 
consisted of patients diagnosed with cancer (cytological or 
histopathological); the most frequent cancers were lung 
cancer (50%), colon cancer (24%), gastric cancer (10%) and 
prostate and bladder cancer (5%). In total, other cancers 
did not exceed 5% referrals. Of the referred subjects found 
with cancer, 91% were qualified for treatment of which 48% 
required radical therapy and 9% symptomatic treatment.
In those 80 subjects referred to the clinic because of 
abnormalities in imaging testing, 50% were detected by 
breast ultrasonography, 10% by mammography, 18% dem-
onstrated thyroid pathologies by ultrasound, 12% by chest 
X-ray and 10% by other image tests. Only the chest X-rays 
Table I. Patient demographics
Gender Number of DILO  
card-bearing patients 
Number of patients 
without DILO cards 
Median age (range) for DILO 
card-bearing patients
Median age (range) for patients 
without DILO cards
Males 265 (23.6%) 114 (10.1%) 67 (18–90) 66 (39–88)
Females 247 (22.0%) 498 (44.3%) 62 (18–88) 52 (18–76)
Total 512 (45.6%) 612 (54.4%) 64 (18–90) 57 (18–88)
Table II. GP referral data
Reasons for referral Number of DILO card-  
-bearing patients (%)
Number of patients  
without DILO cards (%)
Total patients  
(%)
Prophylactic testing for breasts 0 (0%) 286 (46.7%) 286 (25.4%)
For a diagnosis based on interview and/or physical examination 59 (11.5%) 78 (12.8%) 137 (12.2%)
Abnormalities in additional testing 169 (33.0%) 80 (13.1%) 249 (22.2%)
Histopathological or cytological diagnoses of cancer 273 (53.3%) 163 (26.6%) 436 (38.8%)
Other 11 (2.2%) 5 (0.8%) 16 (1.4%)
Total 512 (100%) 612 (100%) 1124 (100%)
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had been previously recommended by their GPs. The other 
imaging tests were recommended by the out-patient spe-
cialist doctors or through private consultation. Cancer was 
diagnosed in 3 cases. Out of the 78 patients referred due to 
pathologies following physical examination or interview, 
22 were diagnosed by cytology or histopathology. In all 
cases this was due to a physically apparent tumour of which, 
in 18 instances, turned out to be a metastatic lymph node or 
a conglomerate of metastatic lymph nodes, whilst 4 cases 
were primary breast tumours. None of these patients were 
qualified for radical treatment.
There were 5 patient referrals that came under the 
‘others’ classification consisting of: lymphadenopathy (2), 
abnormal laboratory findings (2), and fatigue, malaise, and 
weight loss (1). In this group, none were finally diagnosed 
with cancer. As non-DILO card patient referrals to the Cancer 
Clinic did not differ to referrals made during 2010–2013, 
only DILO card-based referrals were further analysed by 
our study.
GP referral data to the Clinic for DILO  
card-bearing patients
All causes for referral in the DILO card-bearing patients 
are presented in Table III and the divisions made according 
to the physicians in setting up the DILO cards are shown in 
Table IV. DILO cards were prepared by 3 groups of physicians 
as follows: GPs, out-patient specialist-care doctors (other 
than those of the Cancer Clinic) and those of the Cancer 
Clinic itself. There were 89% patient subjects where cancer 
had been diagnosed and who were assigned for causative 
treatment, whilst 11% received symptomatic treatment. In 
the 228 patients suspected of cancer, 110 were diagnosed 
through cytology or histopathology; i.e. 44% of which 31 
qualified for radical treatment (31%). Of those 169 Cancer 
Clinic referrals because of abnormalities found in additional 
tests, 80 (47.3%) were diagnosed with cancer. In 59 DILO 
card-bearing subjects in whom no additional tests had been 
performed and who had undergone an interview by their 
physician, only 21 were diagnosed with cancer of which 16 
had a tumour accessible to physical examination.
Discussion
Cancer is one of the common causes of morbidity in the 
modern world. According to WHO (World Health Organisa-
tion), the number of new cases of cancer globally will have 
risen from 15 million in 2000 to 15 million by 2020 [4, 5]. 
Within such data, the countries of South-East Asia and 
Central-Eastern Europe predominate [6]. The effectiveness 
in treating cancer in Poland is also worse than Western 
European countries as confirmed by the Eurocare-3 and 
Eurocare-4 studies [7], where the data from 22 European 
countries was analysed; including Poland. These studies 
indicate that there still exists a gap between Western and 
Eastern parts of Europe. Cancer requires specialised knowl-
edge from doctors on differential diagnostics as well as cy-
tology, cytogenetics, and molecular diagnostics. Individual 
abnormalities found upon physical examination are rarely 
specific enough to enable a disease-type classification. This 
particularly applies to any lesions found by diagnostic imag-
ing as similar aberrations can arise through various diseases; 
often not oncological ones. The ability to differentiate be-
tween lesions that are potentially serious to those that are 
mild or inflammatory upon diagnostic imaging, should be 
a requirement for radiologist physicians. GPs are however 
required to know the correct procedures whenever abnor-
malities are found. Legal amendments made to healthcare 
services have increased the role of GPs concerning oncology, 
and the introduction of DILO cards was intended to reduce 
queuing for patients suspected of cancer, to rationalise 
diagnostics and treatment along with introducing rapid 
diagnoses and comprehensive treatment as well as decreas-
ing cancer patient mortality and decreasing treatment costs 
due to earlier-stage detection of disease. In our case, those 
without DILO cards, radical treatment was undertaken in 
48% cases in whom cancer had been diagnosed. However, 
in DILO patients referred by GPs, cancer was only diagnosed 
in 31% instances. 
Within the ‘oncological package’, diagnostics consists 
of several stages. The first being when patients visit their 
GP, who conducts a detailed interview and assesses their 
ailments, making referrals for further testing that may be 
required; the GP is however not obliged to do the latter. Our 
analyses showed that there were 11.5% of patients who are 
referred to an oncologist without any such further testing 
being done. This is a considerable amount, especially as 
only 35% of these patients are in the end diagnosed with 
cancer. In addition, only 13 of these qualified for radical 
treatment. On the other hand, 16 of these patients had an 
apparently accessible tumour upon physical examination 
of which 12 had breast tumours. The question thus remains 
is as to why the GPs did not in such cases refer the patient 
for diagnostic breast imaging and why was this duty was 
passed onto the specialist physician. In this same group 
referred to cancer specialists, there were 12 patients who 
lost 2-20 kg body weight over 3 months, which to a doc-
tor is symptom of concern. In none of these cases was 
a cancer diagnosis made upon making additional tests 
and 80% were redirected to other specialists based on 
endocrinological or psychiatric diagnoses that were made. 
Interviews that establish colonic abnormalities (presence of 
blood in the faeces, pencil-thin stools etc.) always lead to a 
colonoscopy referral. In 5 out of the 12, colonic cancer had 
been diagnosed. All this leads to the conclusion that 65% 
of patient referrals made to a specialist oncologist based 
on interviews and/or physical examination did not require 
diagnostics by an oncologist. 
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The conclusions from our previous study stated that 
the experience of oncologists suggest that GPs rarely try to 
classify lesions according to diagnostic imaging, but quickly 
refer such patients for oncological consultation. This premise 
was based on the accepted working-practice hypothesis 
that the reasons why most referrals are made to oncologists 
are because of abnormalities found in additional testing but 
not in diagnosing cancer. The presented analyses concern-
ing patients bearing DILO cards unfortunately confirms 
this. In 125 (24.6%) cases, the reasons why DILO cards were 
issued were due to abnormalities in diagnostic imaging. Of 
these, 77 (61%) ended up having a cancer diagnosis where 
the majority showed abnormalities by classic chest X-ray, 
which is a low-sensitivity test. Furthermore, in all cases this 
was just a front-back (AP) projection. The proportion of 
patients qualifying for radical treatment in this group was 
barely 8.7%. In patients referred because of abnormalities 
found by ultrasound of the abdominal cavity, two groups 
can be clearly distinguished. In one are patients showing 
liver lesions, which by further image analysis were found 
to be mild, whilst the other group had liver metastases. 
Similar referral statistics were observed based on breast 
imaging and neck ultrasound. All these patients could have 
been diagnosed by their GPs if they had been authorised to 
issue referrals for CT scans or fine needle aspiration biopsy. 
These competencies/authorisations are at present however 
possessed only by Specialist Clinics and it thus seems that 
in the burden placed on oncologists, as herein described, 
a significant factor may be that other specialist AOS clinics 
are used too little. Even worse are the findings in those re-
ferrals made based on abnormal laboratory test results. In 
43 patients bearing DILO cards for these reasons, barely 3 
were diagnosed with cancer. In all cases, they had elevated 
PSA levels (Prostate Specific Antigen). It is also striking that 
in 33% patients, DILO cards were issued due to abnormali-
ties found in additional testing; for non-DILO card bearing 
patients this was only 13%. This observation may suggest 
that under the guise of having DILO cards, there is hidden 
the willingness for making a rapid diagnosis based on non-
oncological reasons. 
Table III. Most frequent reasons for referring DILO card-bearing patients
Type of disorder Numbers (%) Number of patients finally 
diagnosed with cancer (%)*
Number of patients treated 
radically (%)
Referrals for diagnosis based on interview and/or physical examination abnormalities
Tumour found by physical examination 18 (30.5%) 14 (77.7%) 7 (50%)
Lymphadenopathy 17 (28.8%) 2 (11.8%) 2 (100%)
Blood in stool, abnormal stool passage,  
pencil-thin stools
12 (20.3%) 5 (41.7%) 4 (80%)
Body mass loss 11 (18.6%) 0 (0%) –
Refractory vomiting 1 (1.7%) 0 (0%) –
Total 59 (100%) 21 (35.6%) 13 (62%)
Abnormalities found by additional testing
Abnormalities in chest X-Ray 61 (36.1%) 46 (75.4%) 4 (8.7%)
Abnormalities in abdominal cavity ultrasound 38 (22.5%) 18 (47.4%) 2 (11.1%)
Abnormalities in breast mammography or 
ultrasound 
21 (12.4%) 11 (52.4%) 10 (90.1%)
Abnormalities in neck ultrasound 4 (2.4%) 2 (50%) 2 (100%)
Abnormalities in circulating blood morphology 22 (13.1%) 0 (0%) –
Abnormalities in other tests of circulating blood 21 (12.4%) 3 (14.3%) 0 (0%)
Other 2 (1.2%) 0 (0%) –
Total 169 (100%) 80 (47.3%) 18 (22.5%)
Histopathological or cytological diagnosis of cancer 
Lung cancer 82 (30.0%) 82 (100%) 20 (24.4%)
Breast cancer 80 (29.3%) 80 (100%) 64 (80%)
Colonic cancer 48 (17.6%) 48 (100%) 31 (64.6%)
Stomach cancer 18 (6.6%) 18 (100%) 5 (27.8%)
Prostate cancer 15 (5.5%) 15 (100%) 13 (86.7%)
Others 30 (11.0%) 30 (100%) 7 (23.3%)
Total 273 (100%) 273 (100%) 140 (51.3%)
*Confirmed by histopathology or cytology
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A consequence of taking such actions in this way, is a 
significantly increased number of patients that are required 
to have oncological consultations, which prolongs waiting 
times for their first specialist visit and impedes those seri-
ously ill from being admitted that require rapid interven-
tions. At this point the n = 236 group of DILO card-bearing 
patients (53.3%) with cancer diagnosed by cytology and 
histopathology should be mentioned insomuch that 88% 
had their cards issued by an oncologist physician. In the 
author’s opinion, it is just this group that has gained most 
advantage from rapid diagnostics and the option for estab-
lishing a treatment plan prepared by a multi-disciplinary 
consultation. This is particularly the case if one considers 
that a physician from the Cancer Clinic can issue DILO cards 
Table IV. Most frequent reasons for referring DILO card-bearing patients divided according to physician referrals
Type of disorder Total 
number  
of patients
Number of DILO card-bearing 
patients issued by GPs 
Number of DILO card-bearing 
patients issued by AOS
Number of DILO card-bearing 
patients issued by Cancer Clinic 
physicians
Referrals for diagnosis based on interview and/or physical examination abnormalities 
Tumour found by 
physical examination
18 17 (94%) 1 (6%) 0 (0%)
Lymphadenopathy 17 16 (94%) 1 (6%) 0 (0%)
Blood in stool,  
abnormal stool 
passage, pencil-thin 
stools
12 12 (100%) 0 (0%) 0 (0%)
Body mass loss 11 11 (100%) 0 (0%) 0 (0%)
Refractory vomiting 1 1 (100%) 0 (0%) 0 (0%)
Total 59 57 (97%) 2 (3%) 0 (0%)
Abnormalities found by additional testing
Abnormalities in chest 
X-Ray
61 48 (79%) 4 (7%) 9 (15%)
Abnormalities in 
abdominal cavity 
ultrasound
38 20 (53%) 9 (24%) 9 (24%)
Abnormalities in 
breast mammography 
or ultrasound
21 1 (5%) 1 (5%) 19 (90%)
Abnormalities in neck 
ultrasound
4 3 (75%) 1 (25%) 0 (0%)
Abnormalities in 
circulating blood 
morphology
22 22 (0%) 0 (0%) 0 (0%)
Abnormalities in other 
tests of circulating 
blood
21 19 (14.3%) 2 (0%) 0 (0%)
Others 2 2 (100%) 0 (0%) 0 (0%)
Total 169 115 (68%) 17 (10%) 37 (22%)
Histopathological or cytological diagnosis of cancer 
Lung cancer 82 0 (0%) 20 (24%) 62 (76%)
Breast cancer 80 0 (0%) 0 (0%) 80 (100%)
Colonic cancer 48 1 (2%) 3 (6%) 44 (92%)
Stomach cancer 18 0 (0%) 5 (28%) 13 (72%)
Prostate cancer 15 0 (0%) 8 (53%) 7 (47%)
Others 30 1 (3%) 7 (23%) 22 (73%)
Total 273 2 (1%) 43 (16%) 228 (84%)
All DILO cards
All w/w 511 174 (34%) 62 (12%) 265 (53%)
Proportion of DILO 
cards verified as ‘cancer’ 
72% 48% 90% 88%
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whenever cancer was returned or progression is suspected 
and in this whole group, 51% were qualified for radical 
treatment.
The presented study entirely confirms the accepted 
premise about burdening oncologist physicians with the 
diagnosing of non-cancer patients. A decided majority of 
patients referred to the Cancer Clinic possessing DILO cards 
were those who were not diagnosed with cancer. Our analy-
ses demonstrated the smallest numbers of cancer diagnoses 
in DILO card bearing patients in those without having any 
additional testing done. Furthermore, our results clearly 
show that DILO card bearing patients did not qualify more 
often to radical treatment compared to those without. 
Data analysis of physicians issuing DILO cards clearly 
show that only a very few cards were issued by medical 
specialist compared to those from the Cancer Clinic. Refer-
rals for diagnosis based on interviews and/or abnormalities 
found after physical examination were given only by GPs, 
which is in keeping with the postulates of the ‘oncology 
package’ according to which medical specialist can issue 
DILO cards at the stage at which cancer is confirmed when 
aimed at undertaking a detailed/in depth diagnosis. In such 
cases Cancer Clinic physicians very often decide to issue 
DILO cards We are unable to say whether the small numbers 
of DILO cards issued by medical specialist other than the 
Cancer Clinic is due to local conditions or those imposed 
by the system. We also don’t know how many of the DILO 
cards issued by GPs were rejected by medical specialist other 
than the ones from the Cancer Clinic. Nevertheless, it seems 
to us that the postulates of the ‘oncology package’ do not 
sufficiently detail this issue and, because of this, a stream of 
patients that require specialist diagnosis become redirected 
to Cancer Clinics. A collation of these findings by the fund-
ing body (National Health Insurance) would be interesting. 
The study is the first of its kind, (after the introduction 
of DILO cards), for assessing the structure of admissions to 
regional Cancer Clinics in areas where there are no other 
oncology centres in operation and where there are no pri-
vate oncology services admitting patients. In our opinion, 
a part of the patients could have been kept under obser-
vation for longer by the GPs, which would thereby have 
excluded the ones with transitory and reactive lesions. Some 
of the patients, particularly those with mild lesions to the 
breast or with equivocal lesions detected by imaging of 
the lungs or liver, could have been left under observation 
for longer if GPs had the means for referring fine needle 
aspiration biopsies or CT scans that frequently resolve-away 
any oncological concerns/worries. This especially applies 
to patients with lesions detected by classical X-Ray of the 
chest which appears as a weak shadow or by abnormalities 
in the liver or adrenal gland as revealed by ultrasound of 
the abdominal cavity (corresponding to hepatic angiomas 
and adrenal ademomas). Thus, significant reductions would 
have been made both in the number of patients waiting 
for specialist consultations and in unnecessary diagnoses 
within the framework of having a rapid oncological pathway. 
Nonetheless, patients suffering from proliferative diseases 
require an unreservedly fast consultation. Similarly, urgent 
treatment is necessary for patients with life-threatening 
disorders. Estimating healthcare needs in oncology remains 
an open question for discussion, however there is no inter-
est in this issue and the reasons for this are ambiguous. The 
presented situation leads to an uneven access to oncological 
healthcare throughout the whole of Poland. 
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